Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants

Transplant Proc. 1993 Feb;25(1 Pt 2):1391.

Authors

T D Batiuk¹, J M Barry, W M Bennett, M M Meyer, D Tolzman, D J Norman

Affiliation

¹ Laboratory of Immunogenetics and Transplantation, Oregon Health Sciences University, Portland 97201.

PMID: 8382860

No abstract available

Publication types

Clinical Trial
Comparative Study

MeSH terms

Adenoma, Bile Duct / epidemiology
Age Factors
Azathioprine / therapeutic use
Cyclosporine / therapeutic use
Follow-Up Studies
Humans
Immunosuppression Therapy / adverse effects*
Incidence
Kidney Transplantation / immunology*
Lymphoma / epidemiology
Male
Muromonab-CD3 / adverse effects*
Muromonab-CD3 / therapeutic use
Neoplasms / epidemiology*
Prostatic Neoplasms / epidemiology
Retrospective Studies
Skin Neoplasms / epidemiology
Thyroid Neoplasms / epidemiology

Substances

Muromonab-CD3
Cyclosporine
Azathioprine